Regulation of Glucose Insulinotropic Peptide and Intestinal Glucose Transporters in the Diet-Induced Obese Mouse

J Diabetes Res. 2022 Feb 17:2022:5636499. doi: 10.1155/2022/5636499. eCollection 2022.

Abstract

Our recent studies have shown that glucose-dependent insulinotropic polypeptide (GIP), but not glucagon-like peptide 1 (GLP-1), augments Na-glucose transporter 1- (SGLT1-) mediated glucose absorption in mouse jejunum. Na-dependent glucose absorption sharply rose and peaked in 3 months of high-fat (i.e., obese) compared to normal (i.e., normal weight) diet fed animals. Previous studies have shown that GIP-augmented SGLT1 and PEPT1 (peptide transporter 1) are regulated by protein kinase A (PKA) signaling in mouse jejunum. Additional studies have indicated that cAMP and PI3 kinase signaling augment PEPT1 through EPAC and AKT activation pathways, respectively, through increased apical PEPT1 trafficking in intestinal epithelial cells. However, little is known about how the signaling glucose transport paradigm is altered over a long period. Early on, increased glucose absorption occurs through SGLT1, but as the obesity and diabetes progress, there is a dramatic shift towards a Na-independent mechanism. Surprisingly, at the peak of glucose absorption during the fifth month of the progression of obesity, the SGLT1 activity was severely depressed, while a Na-independent glucose absorptive process begins to appear. Since glucose transporter 2 (GLUT2) is expressed on the apical membrane of the small intestine in obese patients and animal models of obesity, it was hypothesized to be the new more efficient route. Western blot analyses and biotinylation of the apical membrane revealed that the GIP expression increases in the obese animals and its trafficking to the apical membrane increases with the GIP treatment.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Gastric Inhibitory Polypeptide / drug effects*
  • Gastric Inhibitory Polypeptide / metabolism
  • Glucose Transporter Type 4 / drug effects*
  • Glucose Transporter Type 4 / metabolism
  • Jejunum / drug effects
  • Jejunum / metabolism*
  • Mice
  • Mice, Inbred C57BL / metabolism
  • Mice, Obese / metabolism
  • Peptide Fragments / drug effects*
  • Peptide Fragments / metabolism

Substances

  • Glucose Transporter Type 4
  • Peptide Fragments
  • gastric inhibitory polypeptide (3-30)-amide
  • Gastric Inhibitory Polypeptide